Certara, Inc. · NASDAQ:CERT

Certara — Technical Presentation (May 2014)

41 slides from Certara's technical presentation, May 1, 2014

  1. Slide 1: Accelerating Decision-making Related to Cardiac Safety

    Accelerating Decision-making Related to Cardiac Safety Helen Moore, PhD May 1, 2014 1

  2. Slide 2: Today's Presenter

    Today’s Presenter • Helen Moore, PhD – Joined Certara (then Pharsight) in 2009 – Modeling and simulation consultant – Trainer of modeling theory and software – Previous positions at Genentech, the American Institute of Mathematics, Stanford University, Bowdoin College – Expertise in population PK/PD

  3. Slide 3: Agenda

    Agenda • Background and Regulatory Expectations • Overview of Phoenix QT+ for Cardiac Safety Analysis • Streamlined QT Analysis Example in Phoenix QT+ • Q&A © Copyright 2014 Certara, L.P. All rights reserved. 3

  4. Slide 4: Background: Why the Concern and Why QT Analysis?

    Background: Why the Concern and Why QT Analysis? • Drug-induced QT interval prolongation is Anthony Atkielski / Wikimedia Commons / Public Domain a biomarker for torsades de pointes (TdP) • TdP is a heart arrythmia that can lead to sudden death Wikimedia Commons / Public Domain • QT prolongation has

  5. Slide 5: Regulatory Expectations

    Regulatory Expectations • Defines Thorough QT (TQT) Study • If positive, more intensive ECG monitoring is needed in later studies • Explains use of concentration-QTc modeling for better decision-making © Copyright 2014 Certara, L.P. All rights reserved. 5

  6. Slide 6: Overview of Phoenix QT+

    Overview of Phoenix QT+ © Copyright 2014 Certara, L.P. All rights reserved. 6

  7. Slide 7: Phoenix QT+

    Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data © Copyright 2014 Certara, L.P. All rights reserved. 7

  8. Slide 8: Phoenix QT+

    Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin © Copyright 2014 Certara, L.P. All rights reserved. 8

  9. Slide 9: Phoenix QT+

    Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies © Copyright 2014 Certa

  10. Slide 10: Phoenix QT+

    Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies • Can shorten time for

  11. Slide 11: Phoenix QT+ Workflow Objects

    Phoenix QT+ Workflow Objects Heart Rate Correction Data Processing QT Transformations Central Tendency Basic QT Analysis Outlier Analysis Exploratory Plots Concentration- QTc Modeling C-QTc © Copyright 2014 Certara, L.P. All rights reserved. 11

  12. Slide 12: QT+ Workflow to Analyze Study Data

    QT+ Workflow to Analyze Study Data Concentration-QTc Modeling © Copyright 2014 Certara, L.P. All rights reserved. 12

  13. Slide 13: QT+ to Demonstrate Assay Sensitivity

    QT+ to Demonstrate Assay Sensitivity Study demonstrates assay sensitivity © Copyright 2014 Certara, L.P. All rights reserved. 13

  14. Slide 14: QT+ to Test for Positive TQT Study

    QT+ to Test for Positive TQT Study Positive TQT study for NuDrug at 100 mg © Copyright 2014 Certara, L.P. All rights reserved. 14

  15. Slide 15: QT+ to Model Concentration-QTc Relationship

    QT+ to Model Concentration-QTc Relationship Treatment Group Source Concentration Time Prediction 5% Prediction 50% Prediction 95% NuDrug 20 mg Cmax 0.92 2.50 1.26 1.93 2.63 NuDrug 100 mg Cmax 4.84 2.50 6.48 10.23 13.48 NuDrug User 0.75 2.50 1.01 1.59 2.15 NuDrug User 2.50 2.50 3.36 5.29 7.16 Upper 9

  16. Slide 16: Streamlined QT+ Demo

    Streamlined QT+ Demo © Copyright 2014 Certara, L.P. All rights reserved. 16

  17. Slide 17: We Used Phoenix QT+ to Do the Following

    We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay © Copyright 2014 Certara, L.P. All rights reserved. 17

  18. Slide 18: We Used Phoenix QT+ to Do the Following

    We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay • Test to see if a TQT study was positive © Copyright 2014 Certara, L.P. All rights reserved. 18

  19. Slide 19: We Used Phoenix QT+ to Do the Following

    We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay • Test to see if a TQT study was positive • Produce a table of outliers © Copyright 2014 Certara, L.P. All rights reserved. 19

  20. Slide 20: We Used Phoenix QT+ to Do the Following

    We Used Phoenix QT+ to Do the Following: • Confirm sensitivity of the assay • Test to see if a TQT study was positive • Produce a table of outliers • Perform concentration-QTc modeling © Copyright 2014 Certara, L.P. All rights reserved. 20

  21. Slide 21: Recap: Phoenix QT+

    Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data © Copyright 2014 Certara, L.P. All rights reserved. 21

  22. Slide 22: Recap: Phoenix QT+

    Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin © Copyright 2014 Certara, L.P. All rights reserved. 22

  23. Slide 23: Recap: Phoenix QT+

    Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies © Copyright 201

  24. Slide 24: Recap: Phoenix QT+

    Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies • Can shorten t

  25. Slide 25: Recap: Phoenix QT+

    Recap: Phoenix QT+ • Is a collection of easy to use modules for analyzing QT interval data • Has the same user-friendly interface as other Phoenix products such as Phoenix WinNonlin • Can be used throughout drug development, from preclinical to clinical studies, including TQT studies • Can shorten t

  26. Slide 26: Q&A Session on Phoenix QT+ for Cardiac Safety

    Q&A Session on Phoenix QT+ for Cardiac Safety © Copyright 2014 Certara, L.P. All rights reserved. 26

  27. Slide 27: Contacts & Follow-Up: Thank you!

    Contacts & Follow-Up: Thank you! For more information regarding today’s presentation, please contact: • Helen Moore, Senior Scientific Consultant • helen.moore@certara.com For more information on Certara’s products & services, please contact our sales group: Americas India Email: sales@certara.com E

  28. Slide 28: Additional Slides for Viewers of Webinar

    Additional Slides for Viewers of Webinar © Copyright 2014 Certara, L.P. All rights reserved.

  29. Slide 29: Apply Different HR Correction Methods

    Apply Different HR Correction Methods Select HR correction methods © Copyright 2014 Certara, L.P. All rights reserved. 29

  30. Slide 30: Apply Statistical Methods to Evaluate

    Apply Statistical Methods to Evaluate Select statistical evaluation methods © Copyright 2014 Certara, L.P. All rights reserved. 30

  31. Slide 31: Summary Worksheet of Results

    Summary Worksheet of Results Slopes closer to zero for QTcF than QTcP for almost all comparisons © Copyright 2014 Certara, L.P. All rights reserved. 31

  32. Slide 32: QTc vs. RR Plots

    QTc vs. RR Plots Slopes closer to zero for QTcF than QTcB, so select QTcF for further analysis © Copyright 2014 Certara, L.P. All rights reserved. 32

  33. Slide 33: Baseline- & Placebo-Correct QTcF for Analysis

    Baseline- & Placebo-Correct QTcF for Analysis © Copyright 2014 Certara, L.P. All rights reserved. 33

  34. Slide 34: Central Tendency: ΔQTcF vs Time Plots

    Central Tendency: ΔQTcF vs Time Plots Positive TQT study for NuDrug at 100 mg © Copyright 2014 Certara, L.P. All rights reserved. 34

  35. Slide 35: Central Tendency Object: Assay Sensitivity

    Central Tendency Object: Assay Sensitivity Study demonstrates assay sensitivity © Copyright 2014 Certara, L.P. All rights reserved. 35

  36. Slide 36: Outlier Analysis: NuDrug only at 100mg

    Outlier Analysis: NuDrug only at 100mg Default settings (all settings can be customized) © Copyright 2014 Certara, L.P. All rights reserved. 36

  37. Slide 37: Exploratory Plots Object

    Exploratory Plots Object • Mean ΔΔQTc vs. time overlay with mean Conc vs. Time • Individual and mean hysteresis plots • Scatterplots with linear regression line of Conc vs. QTc (ΔQTc, ΔΔQTc, PR, QRS, etc.) © Copyright 2014 Certara, L.P. All rights reserved. 37

  38. Slide 38: C-QTc Object: Linear Model with Intercept

    C-QTc Object: Linear Model with Intercept Theta Worksheet Goodness of Fit © Copyright 2014 Certara, L.P. All rights reserved. 38

  39. Slide 39: C-QTc Object: Linear Model with Time-Intercept

    C-QTc Object: Linear Model with Time-Intercept Theta Worksheet Better precision on slope and lower residual error Goodness of Fit No pattern in residual plots © Copyright 2014 Certara, L.P. All rights reserved. 39

  40. Slide 40: C-QTc Prediction Uses Bootstrap Methodology

    C-QTc Prediction Uses Bootstrap Methodology Enter concentrations for QTcF prediction from final model Enter the number of bootstrap replicates © Copyright 2014 Certara, L.P. All rights reserved. 40

  41. Slide 41: C-QTc Prediction Summary Table and Plot

    C-QTc Prediction Summary Table and Plot Treatment Group Source Concentration Time Prediction 5% Prediction 50% Prediction 95% NuDrug 20 mg Cmax 0.92 2.50 1.26 1.93 2.63 NuDrug 100 mg Cmax 4.84 2.50 6.48 10.23 13.48 NuDrug User 0.75 2.50 1.01 1.59 2.15 NuDrug User 2.50 2.50 3.36 5.29 7.16 Upper 95% C

Certara — Technical Presentation (May 2014) on 6ix